BACKGROUND AND OBJECTIVES: A large number of chromosomal abnormalities have been detected in multiple myeloma (MM). The most frequent are chromosome 13q deletions and translocations affecting the immunoglobulin heavy chain gene (IGH). Recent studies using comparative genomic hybridization (CGH) have shown that gains of 11q represent one of the most frequent genomic changes in MM. However CGH is not generally used in routine clinical laboratories. DESIGN AND METHODS: In the present study, efficiency of fluorescent in situ analysis (FIS)H analysis in the detection of 11q abnormalities in MM patients was investigated. Cytogenetic and FISH studies with three different specific probes for the regions containing the genes BCL1 (11q13), ATM (11q22) and MLL (11q23) were simultaneously performed in 52 patients: 9 cases with 11q abnormalities detected by conventional cytogenetics and 43 cases without 11q abnormalities. FISH analysis identified 11q aberrations that were undetected by cytogenetics in 16 out the 43 cases (37%). RESULTS: Gains on 11q were present in 13 cases (30%) while rearrangements on 11q were observed in the remaining 3 cases. No losses were found. All 11q gains involved the three regions analyzed (BCL1, ATM and MLL genes) while only rearrangements of BCL1 were observed. In all control cases the 11q alterations were confirmed by FISH. A good overall correlation between CGH and FISH was observed. Nevertheless gains on BCL1, ATM and MLL genes were observed in 3 cases displaying a normal CGH. INTERPRETATION AND CONCLUSIONS: In summary, chromosomal abnormalities on 11q are frequent in MM. FISH studies demonstrate a high sensitivity at detecting this abnormality and should be used in the routine evaluation of MM.
BACKGROUND AND OBJECTIVES: A large number of chromosomal abnormalities have been detected in multiple myeloma (MM). The most frequent are chromosome 13q deletions and translocations affecting the immunoglobulin heavy chain gene (IGH). Recent studies using comparative genomic hybridization (CGH) have shown that gains of 11q represent one of the most frequent genomic changes in MM. However CGH is not generally used in routine clinical laboratories. DESIGN AND METHODS: In the present study, efficiency of fluorescent in situ analysis (FIS)H analysis in the detection of 11q abnormalities in MM patients was investigated. Cytogenetic and FISH studies with three different specific probes for the regions containing the genes BCL1 (11q13), ATM (11q22) and MLL (11q23) were simultaneously performed in 52 patients: 9 cases with 11q abnormalities detected by conventional cytogenetics and 43 cases without 11q abnormalities. FISH analysis identified 11q aberrations that were undetected by cytogenetics in 16 out the 43 cases (37%). RESULTS: Gains on 11q were present in 13 cases (30%) while rearrangements on 11q were observed in the remaining 3 cases. No losses were found. All 11q gains involved the three regions analyzed (BCL1, ATM and MLL genes) while only rearrangements of BCL1 were observed. In all control cases the 11q alterations were confirmed by FISH. A good overall correlation between CGH and FISH was observed. Nevertheless gains on BCL1, ATM and MLL genes were observed in 3 cases displaying a normal CGH. INTERPRETATION AND CONCLUSIONS: In summary, chromosomal abnormalities on 11q are frequent in MM. FISH studies demonstrate a high sensitivity at detecting this abnormality and should be used in the routine evaluation of MM.
Authors: Maryam Arefi; Juan L García; M Montserrat Briz; Felipe de Arriba; Juan N Rodríguez; Guillermo Martín-Núñez; Joaquín Martínez; Javier López; Julio G Suárez; M José Moreno; M Angeles Merino; Norma C Gutiérrez; Jesús Marίa Hernández-Rivas Journal: Int J Hematol Date: 2012-07-18 Impact factor: 2.490
Authors: José Angel Hernández; Ana Eugenia Rodríguez; Marcos González; Rocío Benito; Celia Fontanillo; Virgilio Sandoval; Mercedes Romero; Guillermo Martín-Núñez; Alfonso García de Coca; Rosa Fisac; Josefina Galende; Isabel Recio; Francisco Ortuño; Juan Luis García; Javier de las Rivas; Norma Carmen Gutiérrez; Jesús F San Miguel; Jesús María Hernández Journal: Haematologica Date: 2009-03 Impact factor: 9.941
Authors: Cristina Robledo; Juan L García; Rocío Benito; Teresa Flores; Manuela Mollejo; José Ángel Martínez-Climent; Eva García; Norma C Gutiérrez; Miguel A Piris; Jesús M Hernández Journal: PLoS One Date: 2011-09-21 Impact factor: 3.240
Authors: I González-Gascón Y Marín; J A Hernández; A Martín; M Alcoceba; M E Sarasquete; A Rodríguez-Vicente; C Heras; N de Las Heras; R Fisac; A García de Coca; I de la Fuente; M Hernández-Sánchez; I Recio; J Galende; G Martín-Núñez; J M Alonso; J M Hernández-Rivas; M González Journal: Biomed Res Int Date: 2014-03-30 Impact factor: 3.411
Authors: José Perea; Juan Luis García; Jessica Pérez; Daniel Rueda; María Arriba; Yolanda Rodríguez; Miguel Urioste; Rogelio González-Sarmiento Journal: Oncotarget Date: 2017-04-11
Authors: Miguel Quijada-Álamo; María Hernández-Sánchez; Cristina Robledo; Jesús-María Hernández-Sánchez; Rocío Benito; Adrián Montaño; Ana E Rodríguez-Vicente; Dalia Quwaider; Ana-África Martín; María García-Álvarez; María Jesús Vidal-Manceñido; Gonzalo Ferrer-Garrido; María-Pilar Delgado-Beltrán; Josefina Galende; Juan-Nicolás Rodríguez; Guillermo Martín-Núñez; José-María Alonso; Alfonso García de Coca; José A Queizán; Magdalena Sierra; Carlos Aguilar; Alexander Kohlmann; José-Ángel Hernández; Marcos González; Jesús-María Hernández-Rivas Journal: J Hematol Oncol Date: 2017-04-11 Impact factor: 17.388
Authors: José Ángel Hernández; María Hernández-Sánchez; Ana Eugenia Rodríguez-Vicente; Vera Grossmann; Rosa Collado; Cecilia Heras; Anna Puiggros; Ana África Martín; Noemí Puig; Rocío Benito; Cristina Robledo; Julio Delgado; Teresa González; José Antonio Queizán; Josefina Galende; Ignacio de la Fuente; Guillermo Martín-Núñez; José María Alonso; Pau Abrisqueta; Elisa Luño; Isabel Marugán; Isabel González-Gascón; Francesc Bosch; Alexander Kohlmann; Marcos González; Blanca Espinet; Jesús María Hernández-Rivas Journal: PLoS One Date: 2015-12-02 Impact factor: 3.240